Edwards Lifesciences
✦ Quant Fair Value how this is computed
- Implied fair-value range of 36.85-85.47, from this stock's own trailing 5-year average P/E applied to trailing EPS.
- Current price is +66.5% above the average-multiple fair value of 61.16.
Valuation each multiple against its own 5-year range
Vs. peers Medical Devices
| Company | Market cap | P/E (TTM)i | P/Bi | Div yieldi |
|---|---|---|---|---|
| Edwards Lifesciences (EW) | 58.56B | 57.54 | 5.39 | 0.00% |
| Abbott Laboratories (ABT) | 178.39B | 38.29 | 3.50 | 2.41% |
| Medtronic (MDT) | 127.84B | 24.62 | 2.54 | 2.85% |
| Stryker Corp (SYK) | 118.01B | 33.01 | 5.03 | 1.14% |
| Boston Scientific (BSX) | 60.85B | 17.71 | 2.37 | 0.00% |
| GE HealthCare Technologies (GEHC) | 36.46B | 17.05 | 3.14 | 0.17% |
Other StockVane-tracked companies in the same industry.
Morningstar
Trading 9.1% above Morningstar's fair value estimate.
Fair value
Edwards Lifesciences Corp earns a 2-star quantitative star rating, illustrating our stance that this share class is a somewhat unattractive choice, and investors should look elsewhere for more fruitful opportunities. The stock currently trades at a 12% premium over our quantitative fair value estimate of $92.56 per share; however, this estimate should be taken with a pinch of salt due to its medium uncertainty rating.
The firm's lack of profitability undermines our estimated valuation. Companies with low profitability are often less resilient in recessions and are likely to generate weaker future cash flows for shareholders. Reflecting the firm's profitability is its cash flow yield of 2.9%, which ranks in the bottom 40% compared with peers globally. At the current valuation, the yield of cash flow from operations to investors looks paltry. We believe this is a sign that shares could be overvalued.
The firm's valuation metrics are an additional cause for concern. A company's valuation metrics provide insights into the market's expectations for its future growth and profitability. The firm's book value yield of 17.6%, a core component of valuation, falls in the bottom 20% compared with global peers. The market value of this company's shares looks expensive relative to the book (accounting) value of equity, which further promotes our unfavorable price/fair value ratio.
In addition to the aforementioned drivers, our model considers momentum as part of its comprehensive analysis. This share class has outperformed the broader universe over the past year. This outperformance may signify a bull trap, in light of other detractors from our model.
Economic moat
The company's narrow quantitative moat rating indicates it could outearn its cost of capital and maintain robust margins for 10 years or longer. Its moat is bolstered by its strong financial health, which indicates low near-term bankruptcy risk.
By Quantitative Equity Report
Quote time 2026-11-20 20:02:29 · For reference only, not investment advice and not tailored to your situation.
Edwards Lifesciences discussion 0 comments